Evidence map›Paper›PMID 37307602›Full record

ArticleOral oncology2023

Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients.

Can F Koyuncu, Mitchell J Frederick, Lester D R Thompson, Germán Corredor, Sirvan Khalighi, Zelin Zhang, Bolin Song, Cheng Lu, Reetoja Nag, Vidya Sankar Viswanathan and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. CD8JCO precision oncology · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Can F KoyuncuWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Mitchell J FrederickBobby R. Alford Department of Otolaryngology- Head and Neck Surgery, Baylor College of Medicine, Houston, TX, United States.
Lester D R ThompsonHead and Neck Pathology Consultations, Woodland Hills, CA, United States.
Germán CorredorWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Sirvan KhalighiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Zelin ZhangWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Bolin SongWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Cheng LuWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Reetoja NagWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Vidya Sankar ViswanathanWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.
Michael GilkeyAtlanta Veterans Administration Medical Center, Atlanta, GA, United States.
Kailin YangDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland OH, United States.
Shlomo A KoyfmanDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland OH, United States.
Deborah J ChuteDepartment of Pathology, Cleveland Clinic Foundation, Cleveland, OH, United States.
Patricia CastroDepartment of Pathology, Baylor College of Medicine, Houston, TX, United States.
James S LewisDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States; Department of Otolaryngology - Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, United States.
Anant MadabhushiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States; Atlanta Veterans Administration Medical Center, Atlanta, GA, United States. Electronic address: anantm@emory.edu.
Vlad C SandulacheWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States; ENT Section, Operative Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States; Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States. Electronic address: vlad.sandulache@bcm.edu.
Georgia Institute of Technology · USCleveland Clinic · USBaylor College of Medicine · USMichael E. DeBakey VA Medical Center · USVanderbilt University Medical Center · USWoodland Hills Medical Center · US

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
Computer-Assisted Histologic Evaluation of Cardiac Allograft RejectionR01HL151277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MADABHUSHI, ANANT, MARGULIES, KENNETH BER · 2020 to 2023
$3.2M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Prostate cancer risk stratification via computational 3D pathologyR01CA268207 · NCI · UNIVERSITY OF WASHINGTON · PI Jonathan T.C. Liu, Anant Madabhushi · 2022 to 2026
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
Prognostic and Predictive Digital Tissue Image Assay for Prostate CancerR01CA268287 · NCI · EMORY UNIVERSITY · PI GUPTA, SHILPA, LAL, PRITI · 2022 to 2025
$3.0M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
RADIOMIC APPROACHES TO IMPROVE TARGETING FOR ATRIAL FIBRILLATION CATHETER ABLATIONR01HL158071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BARNARD, JOHN, CHUNG, MINA KAY · 2021 to 2024
$2.9M
BLRD VA I01 BX004121BLRD VA IK6 BX006185CSRD VA IK2 CX001953NCATS NIH HHS UL1 TR002548NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS R01 CA257612NCI NIH HHS R01 CA268207NCI NIH HHS R01 CA268287NCI NIH HHS T32 CA094186NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U01 CA269181NCI NIH HHS U24 CA199374NCI NIH HHS U54 CA254566NCRR NIH HHS C06 RR012463NHLBI NIH HHS R01 HL151277NHLBI NIH HHS R01HL15127701A1NHLBI NIH HHS R01 HL158071NHLBI NIH HHS R01 HL15807101A1NIBIB NIH HHS R43 EB028736
6 · The paper itself

Abstract

objectivesMatching treatment intensity to tumor biology is critical to precision oncology for head and neck squamous cell carcinoma (HNSCC) patients. We sought to identify biological features of tumor cell multinucleation, previously shown by us to correlate with survival in oropharyngeal (OP) SCC using a machine learning approach. MATERIALS AND

methodsHematoxylin and eosin images from an institutional OPSCC cohort formed the training set (D

resultsMuNI correlated with overall survival. A multivariable nomogram that included MuNI, age, race, sex, T/N stage, and smoking status yielded a C-index of 0.65, and MuNI was prognostic of overall survival (2.25, 1.07-4.71, 0.03), independent of the other variables. High MuNI scores correlated with depletion of effector immunocyte subsets across all HNSCC sites independent of HPV and TP53 mutational status although the correlations were strongest in wild-type TP53 tumors potentially due to aberrant mitotic events and activation of DNA-repair mechanisms.

conclusionMuNI is associated with survival in HNSCC across subsites. This may be driven by an association between high levels of multinucleation and a suppressive (potentially exhausted) tumor immune microenvironment. Mechanistic studies examining the link between multinucleation and tumor immunity will be required to characterize biological drivers of multinucleation and their impact on treatment response and outcomes.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsHumansPrecision MedicinePrognosisSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentMultinucleationOral cavity cancerTumor infiltrating lymphocytes

Identifiers

PMID37307602
PMCPMC10330801
OpenAlexW4380194010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.